Written Description Prof. Merges 9.13.2011.

Slides:



Advertisements
Similar presentations
35 U.S.C. § 112, First Paragraph By: Sheetal S. Patel.
Advertisements

Written Description: Whats Up With That? Patent Law Sept. 9, 2004 Prof Merges.
Patent Law and Policy University of Oregon Law School Fall 2009 Elizabeth Tedesco Milesnick Patent Law and Policy, Fall 2009 Class 5, Slide 1.
Written Description and Novelty Intro to IP Prof Merges –
Enablement and Written Description Intro to IP – Prof Merges Jan. 19, 2012.
Proteomics Examination Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703)
BLAW 2010 Patent Project Part 1I. Why do we have patent laws?
35 USC §112, First Paragraph, Written Description
1 1 1 AIPLA American Intellectual Property Law Association Standard for Indefiniteness– Nautilus, Inc. v. Biosig Instruments, Inc. Stephen S. Wentsler.
1 35 U.S.C. § 112, first paragraph and the Wands Analysis Remy Yucel, SPE 1636 (571)
UNITED STATES PATENT AND TRADEMARK OFFICE A full transcript of this presentation can be found under the “Notes” Tab. Claim Interpretation: Broadest Reasonable.
1 Rule 132 Declarations and Unexpected Results Richard E. Schafer Administrative Patent Judge Board of Patent Appeals and Interferences.
1 35 USC 112, 1 st paragraph enablement Enablement Practice in TC 1600 Deborah Reynolds, SPE
The America Invents Act (AIA) - Rules and Implications of First to File, Prior Art, and Non-obviousness -
35 U.S.C. 112, Sixth Paragraph MPEP 2181 – 2186 Jean Witz Quality Assurance Specialist Technology Center 1600.
Invention Spotting – Identifying Patentable Inventions Martin Vinsome June 2012.
Memorandum - 35 U.S.C. 112, Second and Sixth Paragraphs Robert Clarke Director, Office of Patent Legal Administration United States Patent and Trademark.
Claim Interpretation By: Michael A. Leonard II and Jared T. Olson.
“REACH-THROUGH CLAIMS”
ENABLEMENT / WRITTEN DESCRIPTION PATENT PROSECUTION PRACTICE Presented at: Webb & Co. Rehovot, Israel Date: February 21, 2013 Presented by: Roy D. Gross.
Patent Processing – Examination Issues Patent, Trademark, and Copyright - Law and Policy 5-8 November 2007 Amman, Jordan Global Intellectual Property Academy.
Side 1 Andrew Chin AndrewChin.com What Metaphysics Can Tell Us About Law Steven D. Smith (2006): Do we hold outdated conceptions.
Intellectual Property Boston College Law School February 25, 2008 Patent - Utility.
Doctrine of Equivalents Intro to IP – Prof Merges
Intellectual Property Boston College Law School February 28, 2007 Patent - Enablement.
Intellectual Property Boston College Law School February 27, 2008 Patent - Enablement.
Intellectual Property
Enablement and Written Description Prof. Robert Merges
Patent Overview by Jeff Woller. Why have Patents? Patents make some people rich – but, does that seem like something the government should protect? Do.
Juicy Whip, Inc. v. Orange Bang, Inc., 51 U.S.P.Q.2d 1700 (Fed.Cir. 1999)
Patents 101 April 1, 2002 And now, for something new, useful and not obvious.
Patent Infringement II Intro to IP – Prof Merges
Written Description II Prof Merges Feb. 4, The Written Description Requirement Gentry Gallery, Inc. v. Berkline Corp., 134 F.3d 1473 (Fed. Cir.
By Paul J. Lee. Disclaimer The opinions and views expressed in these materials are not necessarily those of DexCom and reflect only the personal views.
Examination Issues: Immunology Yvonne (Bonnie) Eyler Quality Assurance Specialist Technology Center 1600 USPTO (571)
SECTION 101 OF THE PATENT LAW Describes what is patentable subject matter: "Whoever invents or discovers any new and useful process, machine, manufacture,
Stem Cells Peter Paras, Jr.. 2 Overview Introduction — Definitions Types of Stem Cells — Origin Examination of Stem Cell Claims — Statutes — Sample Claims.
Utility Requirement in Japan Makoto Ono, Ph.D. Anderson, Mori & Tomotsune Website:
SECTION 101 OF THE PATENT LAW Describes what is patentable subject matter: "Whoever invents or discovers any new and useful process, machine, manufacture,
Broadening the Scope of the Claims in Gene Therapy Applications Deborah Reynolds Detailee, TCPS
Defenses Not Based on Prior Art  Indefiniteness  Nonenablement  Written description  Inventorship  Laches  Equitable estoppel  Statute of limitations.
The Patent Document II Class Notes: January 23, 2003 Law 677 | Patent Law | Spring 2003 Professor Wagner.
Prosecution Group Luncheon November, Prioritized Examination—37 CFR “No fault” special status under 1.102(e) Request made with filing of nonprovisional.
Overcoming Prior Art References Non-Enabling Prior Art References Gary Kunz SPE Art Unit 1616.
PatentEng-Berkeley-Lavian Week 6: Validity and Infringement 1 Patent Engineering IEOR 190G CET: Center for Entrepreneurship &Technology Week 6 Dr. Tal.
35 U.S.C. 112, Second Paragraph Examination Memorandum Robert Clarke Director, Office of Patent Legal Administration United States Patent and Trademark.
1 Written Description Analysis and Capon v. Eshhar Jeffrey Siew Supervisory Patent Examiner AU 1645 USPTO (571)
The Written Description Requirement Why It’s a Good Thing (Seriously) AIPLA Spring Meeting Thursday, May 12, 2011 Amy E. Hamilton Vice President/Deputy.
Patentability of Reach-Through Claims Brian R. Stanton Practice Specialist Technology Center 1600 (703)
New Sections 102 & 103 (b) Conditions for Patentability- (1) IN GENERAL- Section 102 of title 35, United States Code, is amended to read as follows: -`Sec.
1 Demystifying the Examination of Stem Cell-Related Inventions Remy Yucel, Ph.D. Supervisory Patent Examiner Technology Center 1600 United States Patent.
Examining Claims for Compliance with 35 U.S.C. 112(a): Part II – Enablement Focus on Electrical/Mechanical and Computer/Software-related Claims August.
Vector Claims in Gene Therapy Applications: In vivo vs. In vitro Utilities Deborah Reynolds SPE GAU
1 Enablement Issues in Pharmaceutical Claims Joseph K. M c Kane Supervisory Patent Examiner Art Unit Ardin Marschel Supervisory Patent.
Examination Practice in Applications Presenting “Reach-Through Claims” George Elliott Practice Specialist Technology Center 1600
Patents II Disclosure Requirements Class 12 Notes Law 507 | Intellectual Property | Spring 2004 Professor Wagner.
Korean Intellectual Property Office October 19, 2011 Sunhee Lee, SUGHRUE MION PLLC RECENT CASES IN BIOTECH/PHARM/CHEM & 2011 AMERICA INVENTS ACT.
July 13, 2016 Patent Technology Centers 3600 & 3700 Customer Partnership 112(b) Discussion Ashok K. Mannava
AIPLA ID Committee Meeting AIPLA Spring Meeting (Seattle) May 2, 2013
Keiko K. Takagi Sughrue Mion, PLLC
Enablement and Written Description
Ram R. Shukla, Ph.D. SPE AU 1632 & 1634 Technology Center
OTHER INVALIDITY CHALLENGES
Global Innovation Management Workout on Writing a Patent
Law 677 | Patent Law | Spring 2003
Enzo Biochem, Inc. v. Gen-Probe Inc. 323 F. 3d 956 C. A. Fed. (N. Y
Patents II Disclosure Requirements
Stem Cells Peter Paras, Jr.
Examination Practice in Applications Presenting “Reach-Through Claims”
Examination Issues: Immunology
Presentation transcript:

Written Description Prof. Merges 9.13.2011

Gentry Gallery & Ariad Written description: re-emergence, growth in 1990s Challenges Resolution: Ariad, 2010

Gentry Gallery Facts: Invention Doctrine How does written description differ from enablement?

The Written Description Requirement Gentry Gallery, Inc. v. Berkline Corp., 134 F.3d 1473 (Fed. Cir. 1998). Gentry was granted a patent for a sectional sofa comprised of a pair of reclining seats that faced the same direction. Claim 1, the broadest claim, identifies a “fixed console” between the pair of seats. Claims 9, 10, 12-15, and 19-21 are directed to a sectional sofa in which the control means are specifically located on the console. Gentry’s Patent:

US Pat. No. 5,064,244

Claim 1 A sectional sofa comprising: a pair of reclining seats disposed in parallel relationship with one another in a double reclining seat sectional sofa section being without an arm at one end . . . , each of said reclining seats having a backrest and seat cushions and movable between upright and reclined positions . . . ,

a fixed console disposed in the double reclining seat sofa section between the pair of reclining seats and with the console and reclining seats together comprising a unitary structure, said console including an armrest portion for each of the reclining seats; said arm rests remaining fixed when the reclining seats move from one to another of their positions,

Claim 1 (cont’d) and a pair of control means, one for each reclining seat; mounted on the double reclining seat sofa section . . . .

“Object of the invention” language

From the specificiation

Casebook p. 177 “In this case, the original disclosure clearly identifies the console as the only possible location for the controls. It provides for only the most minor variation in the location of the controls, noting that the control “may be mounted on top or side surfaces of the console rather than on the front wall . . . Without departing from this invention.”

“[T]he only discernible purpose for the console is to house the controls. As the disclosure states, identifying the only purpose relevant to the console, “[a]nother object of the present invention is to provide . . . a console positioned between [the reclining seats] that accommodates the controls for both of the reclining seats.”

Casebook, p. 177 Thus, locating the controls anywhere but on the console is outside the stated purpose of the invention.

“[A]lthough not dispositive, because one can add claims to a pending application directed to adequately described subject matter, Sproule [the inventor] admitted at trial that he did not consider placing the controls outside the console until he became aware that some of Gentry’s competitors were so locating the recliner controls.”

“Misappropriation by claim amendment” Merges, Software and Patent Scope: A Report from the Middle Innings, 85 Tex. L. Rev. 1528 (2007).

Enabled?

See discussion n. 1 p. 178 What is the relationship between enablement and written description?

Patent Specification Enabled subject matter: everything the inventor teaches to one of skill in the art. Enabled Specification Described embodiments of the invention: everything the inventor “adequately describes” to one in the art; everything the inventor shows she is in “possession of” or contemplates as embraced by her invention Described Claim 1 Original Application Claim 2 Claimed in C-I-P or amended application

Specification Re-filed If the inventor re-files the specification at a later date, she cannot claim what the first filing enabled but failed to describe. Enabled Described Claim 2 Enabled Described Claim 1 Original Application

Dedicated to the Public What’s claimable? Dedicated to the Public Competitor Original Description Competitor Taught by Patent Competitor Claimable by original inventor

Gentry Gallery v. Berkline Corp. Enabled: 2 reclining seats in a sectional sofa; controls not located on arms of chair Enabled Specification for Gentry patent Described: pair of reclining seats in a sectional sofa with a fixed console that houses the control means Described Claim 1 Claimed: pair of reclining seats in a sectional sofa, a fixed console, and a pair of controls.

Signs of Resistance I Rader, J., in Moba v. Diamond Automation, 325 F.3d 1306, 1322 (Fed. Cir. 2003): “By making written description a free-standing disclosure doctrine, this court produces numerous unintended and deleterious consequences.”

Signs of Resistance II Follows a similar criticism in Enzo Biochem, Inc. v. Gen-Probe, Inc., 323 F.3d 956, 976 (Fed. Cir. 2002) (Rader, J., dissenting from denial of rehearing en banc)

Who is Judge Rader’s Audience? The Supreme Court? Signs of re-engagement with patent law, 1995 (Markman) -2003 (Festo) But of course, only a limited patent diet Disappointment over Madey v. Duke Univ.

A Normative Interlude What’s wrong with the Written Description requirement? Diversion of R&D resources . . .

Calling the question: Ariad Chosen as the vehicle to test Federal Circuit commitment to a separate written description doctrine

Ariad: background NF-kB: gene expression stimulator Researchers discovered its structure and how to block its effects

80. [A method for modifying effects of external influences on a eukaryotic cell, which external influences induce NF-kB-mediated intracellular signaling, the method comprising altering NF-kB activity in the cells such that NF-kB-mediated effects of external influences are modified, wherein NF-êB activity in the cell is reduced] wherein reducing NF-kB activity comprises reducing binding of NF-kB to NF-kB recognition sites on genes which are transcriptionally regulated by NF-kB.

The claims are thus genus claims, encompassing the use of all substances that achieve the desired result of reducing the binding of NF-kB to NF-kB recognition sites. Furthermore, the claims, although amended during prosecution, use language that corresponds to language present in the priority application. . . . The specification also hypothesizes three types of molecules with the potential to reduce NF-kB activity in cells: decoy, dominantly interfering, and specific inhibitor molecules. -- Book supp. P. 61

Ariad’s reading of 112: The specification shall contain [A] a written description [i] of the invention, and [ii] of the manner and process of making and using it, [B] in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same ...

Lilly’s reading (1) “The specification shall contain a written description of the invention, and ” (2) “The specification shall contain a written description ... of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and ” . . . .

We agree with Lilly and read the statute to give effect to its language that the specification “shall contain a written description of the invention” and hold that § 112, first paragraph, contains two separate description requirements: a “written description [i] of the invention, and [ii] of the manner and process of making and using [the invention”]. 35 U.S.C. § 112, ¶ 1 … -- Casebook supp at 64

What is the requirement? “possession as shown in the disclosure” is a more complete formulation. Yet whatever the specific articulation, the test requires an objective inquiry into the four corners of the specification from the perspective of a person of ordinary skill in the art. Based on that inquiry, the specification must describe an invention understandable to that skilled artisan and show that the inventor actually invented the invention claimed.

For example, a generic claim may define the boundaries of a vast genus of chemical compounds, and yet the question may still remain whether the specification, including original claim language, demonstrates that the applicant has invented species sufficient to support a claim to a genus.

although written description and enablement often rise and fall together, requiring a written description of the invention plays a vital role in curtailing claims that do not require undue experimentation to make and use, and thus satisfy enablement, but that have not been invented, and thus cannot be described. For example, a propyl or butyl compound may be made by a process analogous to a disclosed methyl compound, but, in the absence of a statement that the inventor invented propyl and butyl compounds, such compounds have not been described and are not entitled to a patent.

See In re DiLeone, 58 C. C. P. A. 925, 436 F. 2d 1404, 1405 n See In re DiLeone, 58 C.C.P.A. 925, 436 F.2d 1404, 1405 n. 1 (1971) (“[C]onsider the case where the specification discusses only compound A and contains no broadening language of any kind. This might very well enable one skilled in the art to make and use compounds B and C; yet the class consisting of A, B and C has not been described.”).